Recombinant Modified Vaccinia Virus Ankara Provides Durable Protection Against Disease Caused by an Immunodeficiency Virus As Well As Long-term Immunity to an Orthopoxvirus in a Non-human Primate.
From: Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 33, Room 1E19, 33 North Drive, MSC 3210, Bethesda, MD 20892, USA. pearl@niaid.nih.gov
Virology
- Publish Date: Sep 2007
- ISSN: 0042-6822
- Volume: 366
- Issue: 1
- Pages: 84-97
- Medium: Print
- Language: English
- Citation (JAMA): Earl Patricia L, Americo Jeffrey L, Wyatt Linda S, et al. Recombinant Modified Vaccinia Virus Ankara Provides Durable Protection Against Disease Caused by an Immunodeficiency Virus As Well As Long-term Immunity to an Orthopoxvirus in a Non-human Primate.. Virology Sep 2007;366:84-97
Abstract
Recombinant and non-recombinant modified vaccinia virus Ankara (MVA) strains are currently in clinical trials as human immunodeficiency virus-1 (HIV) and attenuated smallpox vaccines, respectively. Here we tested the ability of a recombinant MVA delivered by alternative needle-free routes (intramuscular, intradermal, or into the palatine tonsil) to protect against immunodeficiency and orthopoxvirus diseases in a non-human primate model. Rhesus macaques were immunized twice 1 month apart with MVA expressing 5 genes from a pathogenic simian human immunodeficiency virus (SHIV)/89.6P and challenged intrarectally 9 months later with the pathogenic SHIV/89.6P and intravenously 2.7 years later with monkeypox virus. Irrespective of the route of vaccine delivery, binding and neutralizing antibodies and CD8 responses to SHIV and orthopoxvirus proteins were induced and the monkeys were successively protected against the diseases caused by the challenge viruses in unimmunized controls as determined by viral loads and clinical signs. These non-human primate studies support the clinical testing of recombinant MVA as an HIV vaccine and further demonstrate that MVA can provide long-term poxvirus immunity, essential for use as an alternative smallpox vaccine.
Mesh Headings (Keywords): AIDS Vaccines, Animals, CD4-Positive T-Lymphocytes, Orthopoxvirus, Poxviridae Infections, Primate Diseases, Primates, Recombinant Proteins, Simian Acquired Immunodeficiency Syndrome, T-Lymphocytes, Vaccinia virus, Viral Proteins, Viral Vaccines
Check for Full Text / PubMed Unique Identifier (PMID): 17499326
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.